Arsenic Trioxide (ATO)

DRUG5 trials

Conditions

Acute Myelogenous LeukemiaAcute Promyelocytic LeukemiaAcute Promyelocytic Leukemia (APL)Advanced Pancreatic Ductal AdenocarcinomaLow-risk Myelodysplastic Syndromes

Phase 1

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

RecruitingNCT06670222

Groupe Francophone des MyelodysplasiesLow-risk Myelodysplastic Syndromes

Start: 2025-07-22End: 2027-07-31Target: 24Updated: 2025-07-31

ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

Not yet recruitingNCT07348107

Daniel BreadnerAdvanced Pancreatic Ductal Adenocarcinoma

Start: 2026-02-15End: 2027-03-01Target: 10Updated: 2026-01-16

Phase 2

Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia

TerminatedNCT00184054

University of Southern CaliforniaAcute Myelogenous Leukemia

Start: 2002-04-30End: 2011-08-31Updated: 2014-07-25

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

CompletedNCT00413166

M.D. Anderson Cancer CenterAcute Promyelocytic Leukemia

Start: 2006-12-31End: 2016-02-29Updated: 2019-05-07

Unknown Phase

Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia

Active, not recruitingNCT07187505

Anhui Medical UniversityAcute Promyelocytic Leukemia (APL)

Start: 2025-07-01End: 2027-07-01Target: 28Updated: 2025-09-23

Related Papers

Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia

Blood2015-12-032 citations

Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin